Common insecticides have been linked in studies to neurodevelopmental disorders.

Published Date: 26 Apr 2023

According to a recent study from The University of Toledo, even at levels that are currently recognized, early exposure to the common class of insecticides known as pyrethroids may increase the risk of autism and other developmental disorders.

Read Full News

Latest News

NeuroVoices: Bruce Bebo, PhD, on Big Bets for Breakthroughs and the Campaign to End MS Bruce Bebo, PhD, Isabella Ciccone, MPH

The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.

CALLIPER Extension Data Show Sustained Disability Outcomes With Vidofludimus Calcium in Progressive MS Isabella Ciccone, MPH

Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.

FDA Grants Fast Track to AV-1959R for Alzheimer Prevention Matt Hoffman

Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.

Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis Marco Meglio

Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.

Divozilimab Cuts Relapse Risk at 1 Year in Phase 3 AQUARELLE Trial of NMOSD Marco Meglio

One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.

Clene Submits NDA Seeking Accelerated Approval for ALS Drug Marco Meglio

Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years of evolving FDA guidance.

Todays Updates

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Virtual Pulmonary Rehab and Matched Care, With Omid Pourshahid, MD Omid Pourshahid, MD

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Experts Examine Biologic Coverage in Asthma and COPD

Experts Examine Biologic Coverage in Asthma and COPD

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Todays Updates

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Virtual Pulmonary Rehab and Matched Care, With Omid Pourshahid, MD Omid Pourshahid, MD

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Experts Examine Biologic Coverage in Asthma and COPD

Experts Examine Biologic Coverage in Asthma and COPD

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Latest News

The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.

Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.

Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.

Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.

One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.

Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years of evolving FDA guidance.

News All Time

NeurologyLive® Friday 5 — October 16, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis Marco Meglio

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease Marco Meglio

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Episode 177: Previewing the 2026 NEALS Annual Meeting Marco Meglio, Jinsy A. Andrews, MD, MSc, Nicholas Maragakis, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]

FDA Grants Fast Track Status to EG-501 in Neuropsychiatric Lupus Marco Meglio

The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.

TSHA-102 Produces Multidomain Functional Gains in Rett Syndrome Matt Hoffman

All 10 REVEAL Part A participants gained or regained at least 1 developmental milestone after a single intrathecal TSHA-102 dose, with no treatment-related SAEs reported.

MDS Congress 2026: Late-Breaking Data Snapshot Marco Meglio

A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.

Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial Louie Pasculli

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy Marco Meglio

The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.

ELEVIDYS Shows Sustained Functional Differences vs External Controls in Older Ambulatory Duchenne Patients Louie Pasculli

New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with delandistrogene moxeparvovec, while separate findings characterized micro-dystrophin expression in children younger than 3 years.

Dompé Begins Phase 2 Trial Testing Intranasal Nerve Growth Factor for Cerebral Palsy Marco Meglio

The Galassia trial will evaluate the safety and tolerability of intranasal cenegermin in about 60 children with spastic cerebral palsy across Italy.

Fenfluramine Shows Consistent Seizure Reduction Across Age Groups in CDKL5 Deficiency Disorder Isabella Ciccone, MPH

An analysis of the phase 3 GEMZ trial presented at CNS 2026 showed that fenfluramine produced comparable seizure reductions and safety outcomes in children and adults with CDKL5 deficiency disorder.

Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis Marco Meglio

New 48-week phase 3 data show many patients with generalized myasthenia gravis reached minimal symptom expression on telitacicept, and most who did sustained it.

Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression Isabella Ciccone, MPH

A post hoc analysis of the phase 2/3 NPC002 trial presented at CNS 2026 showed that the benefit of arimoclomol plus miglustat in Niemann-Pick disease type C emerged as early as 3 months after treatment initiation.

NeuroVoices: Ali Habib, MD, on Cemdisiran and the Phase 3 NIMBLE Trial Data in Myasthenia Gravis Marco Meglio, Ali Habib, MD

The professor of neurology and program director of Neuromuscular Medicine at UC Irvine, discusses phase 3 NIMBLE trial findings for cemdisiran in generalized myasthenia gravis, including its novel siRNA mechanism, efficacy, and hospitalization data.

This Week on NeurologyLive® — October 12, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Recommended News For You

Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.

Lung cancer screening adherence rates decline annually after baseline screening

World's premier cancer institute faces crippling cuts and chaos

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

PSA Screening Overdiagnosis Rises Sharply With Age

The self-sacrificing nature of breast cancer cells has been identified as a possible reason for relapse.

'The Pitt' Actor's Cancer Diagnosis; New HHS Research Plans; Madonna Reveals Injury

Recommended Articles For You

Polycythemia Vera: A Historical Perspective and Contemporary Management 

A Visual Journey Through Penile Cancer: Examining the Impact of Photos 

Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions 

Degrader Antibodies for Plasma Cells: Mechanisms, Clinical Potential, and Emerging Therapies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study Hints at Survival Benefit With Transplant for Metastatic Lung Cancer

2.

Is Shorter Radiation Linked to Lymphedema in Breast Cancer?

3.

Obesity-associated cancers tripled nationwide over past two decades

4.

Patellar Resurfacing in Total Knee Replacement; Patient Messaging Trends

5.

Germline Variants Predict Lobular Breast Cancer Recurrence

1.

Unlocking the Mystery of Basilar Artery Stroke: A New Approach to Treatment

2.

Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians

3.

Everything You Need To Know About Trichelemmal Cysts: Symptoms, Causes, Diagnosis And Treatment

4.

Cancer Care and Geographic Inequality: Bridging the Gap in Oncology Outcomes

5.

Advanced Directions in Oncology and Quality Improvement

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion

2.

Navigating the Complexities of Ph Negative ALL - Part II

3.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

4.

From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL

5.

Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot